<DOC>
	<DOCNO>NCT02565147</DOCNO>
	<brief_summary>The purpose study evaluate whether use bivalirudin reduce extent damage do heart muscle patient suffer heart attack , compare comparator treatment ( heparin ) .</brief_summary>
	<brief_title>Bivalirudin Infusion Ventricular Infarction Limitation</brief_title>
	<detailed_description>The study assess effect bivalirudin administration primary percutaneous coronary intervention ( PPCI ) 4 hour ( h ) afterwards , look contrast enhance cardiac magnetic resonance imaging ( CMR ) assess infarct size circulate marker thrombosis cell injury subject treat PPCI large myocardial infarction ( MI ) . The objective study determine whether bivalirudin , compare unfractionated heparin ( UFH ) , primary percutaneous coronary intervention ( PPCI ) large ST segment elevation myocardial infarction ( STEMI ) : Primary Objective - Reduce infarct size assess cardiac magnetic resonance imaging ( CMR ) 5 ( define 5 day ± 36 h randomisation ) day PPCI Secondary Objectives - Improve CMR derive parameter myocardial recovery 5 day PPCI ( i.e . leave ventricular ejection fraction [ LVEF ] , myocardial salvage index [ MSI ] micro-vascular obstruction [ MVO ] ) . - Improve LVEF CMR 90 day - Modulate marker thrombin activity cell injury reperfusion Approximately 200 subject randomize . Subjects stratify prior randomization accord : ) total duration ischemic pain ( &lt; 6 h vs. ≥6 h ) , b ) site . Diagnosis Main Criteria Selection : Adult subject ( ≥18 year ) onset symptom &gt; 20 minute ( min ) &lt; 12 h enrol base diagnosis STEMI ST segment elevation ≥1 mm ≥2 contiguous precordial lead , presumably new leave bundle branch block Thrombolysis Myocardial Infarction ( TIMI ) 0 1 flow infarct relate artery ( IRA ) fulfill angiographic criteria/score large infarction candidate PPCI . All subject receive soon logistically feasible : aspirin ( 150-325 milligram [ mg ] orally , 250 500 mg intravenously [ IV ] ) load dose approve P2Y12 inhibitor unless already maintenance dose . Bivalirudin administer time PPCI approve dose 0.75 mg/kg bolus follow 1.75 mg/kg/h infusion continue 4 h completion index procedure . Subjects randomize UFH treat accord institutional protocol ( include time dose UFH bolus ) . A target activate clotting time ( ACT ) ≥250 second ( ) recommend . Criteria Evaluation : Primary Endpoint : • Infarct size assess CMR 5 day post-PPCI Secondary Endpoints : - CMR MVO assessment 5 day - CMR MSI 5 day - CMR assessment LVEF 5 day - CMR assessment LVEF 90 day - TIMI flow Myocardial Blush Grade ( MBG ) end PPCI - In-hospital net adverse clinical event ( NACE ) 5 day discharge , whichever come first ( death , re-infarction , ischaemia drive revascularisation [ IDR ] , Bleeding Academic Research Consortium [ BARC ] ≥3 bleed ) - Death 90 day Exploratory assessment • Assess pattern comparator group various peri-procedural time point respect limited : micro-particle release , thrombin anti thrombin complex ( TAT ) , myeloperoxidase ( MPO ) Sub-study : • Index microcirculatory resistance ( IMR ) collateral flow index ( CFI ) sub-study</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . ≥ 18 year 2 . Experience ischemic symptom &gt; 20 min &lt; 12 h diagnosis STEMI ST segment elevation ≥1 mm ≥2 contiguous precordial lead , presumably new leave bundle branch block 3 . 3 . Provide write informed consent witness consent country sit patient consent applicable , initiation study relate procedure 4 . Have TIMI 0 1 flow IRA initial angiogram 5 . Fulfill angiographic criteria/score large infarction base initial angiogram ( APPROACH score ≥21 ; see Appendix 1 ) 6 . Are candidate PPCI 7 . Administration initial dose 150325 mg orally ( 250500 mg IV ) load dose approve P2Y12 inhibitor 1 . Contraindication know hypersensitivity bivalirudin UFH 2 . Refusal receive blood transfusion/products 3 . Subjects require stag coronary artery bypass graft ( CABG ) procedure within first 90 day 4 . Known international normalize ratio ( INR ) ≥ 2 know prothrombin time ( PT ) &gt; 1.5 time upper limit normal day index PPCI , know history bleed diathesis 5 . Therapy vitamin K antagonist ( VKA ) , within 72 h PPCI 6 . Therapy dabigatran , rivaroxaban oral antiXa antithrombin agent within 48 h PPCI 7 . History hemorrhagic stroke , intracranial hemorrhage , intracerebral mass , aneurysm , arteriovenous malformation , recent head injury ( within last 5 day ) 8 . Subjects previous history Qwave MI 9 . Known glomerular filtration rate ( GFR ) &lt; 30 milliliter ( mL ) /minute ( min ) dialysis dependent 10 . Major surgery within previous 30 day 11 . Minor surgery/biopsy exclusion past 3 day 12 . Upper gastrointestinal genitourinary bleed 30 day prior randomization 13 . Stroke transient ischemic attack 30 day prior randomization 14 . Administration thrombolytic GPI 72 h prior PPCI 15 . Administration enoxaparin 8 h prior PPCI 16 . Administration bivalirudin 12 h prior PPCI 17 . Administration fondaparinux LMWH 24 h prior PPCI 18 . Known contraindication aspirin P2Y12 inhibitor 19 . Known allergy premedicated iodinate contrast 20 . Known contraindication CMR 21 . Women child bear potential1 22 . Previous enrolment study 23 . Treatment investigational drug device within 30 day precede enrolment plan use investigational drug device primary endpoint study reach 24 . Patients body weight &gt; 150 kg Child bear potential define : A female patient consider childbearing potential unless meet least one follow criterion : Age ≥50 year naturally amenorrhoeic ≥ 1 year* . Premature ovarian failure confirm specialist gynaecologist . Previous bilateral salpingo‐oophorectomy , hysterectomy . XY genotype , Turner 's syndrome , uterine agenesis . *Amenorrhoea follow cancer therapy rule childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>STEMI , infarct size , CMR , bivalirudin</keyword>
</DOC>